Page 15 - Mcdavid Stilwell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

- Toripalimab data will also be featured in ASCO's official press program -SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences"

United statesPatricia keeganJunshi bioscienceEli lillyMcdavid stilwellDenise powellJunshi biosciencesCoherus biosciencesExchange commission onCoherus biosciences incShanghai junshi biosciences co ltdCommittee on foreign investmentPr teamAbbvie incInstitute of microbiology chinese academy scienceIr team

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

June 3, 2021, 5:00 p.m. Eastern Daylight Time “We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited.” In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer and hepatobiliary mal

United statesSan franciscoPatricia keeganJunshi bioscienceEli lillyMcdavid stilwellDenise powellJunshi biosciencesCoherus biosciencesInstitute of microbiology chinese academy scienceIr teamCoherus biosciences incDrug administrationGenentech incShanghai junshi biosciences co ltdExchange commission

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

Bookmark of this page has been deleted. Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. ( CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC), has achieved the pre-specified primary endpoints of progression free survival (PFS) and overall survival (OS) at the interim analysis. JUPITER-06 is a randomized, double-blind, placebo-controlled, multi-center, phase 3 clinical trial initiated in 2019 with 514 patients enrolled.

United statesRuihua xuDenise powellMcdavid stilwellJunshi bioscienceCoherus biosciencesJunshi biosciencesExchange commission onCoherus biosciences incDrug administrationGenentech incData monitoring committeeSun yat sen university cancer hospitalExchange commissionCommittee on foreign investmentAbbvie inc

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United statesRuihua xuDenise powellMcdavid stilwellJunshi bioscienceCoherus biosciencesJunshi biosciencesCoherus biosciences incDrug administrationGenentech incData monitoring committeeSun yat sen university cancer hospitalExchange commissionCommittee on foreign investmentAbbvie incIndependent data monitoring committee

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U S FDA for the Treatment of Nasopharyngeal Carcinoma

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U S FDA for the Treatment of Nasopharyngeal Carcinoma
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoPatricia keeganDenny lanfearJunshi bioscienceEli lillyMcdavid stilwellJunshi biosciencesCoherus biosciencesExchange commission onCoherus biosciences incShanghai junshi biosciences co ltdCommittee on foreign investmentPr teamAbbvie incInstitute of microbiology chinese academy science